These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 7781150)

  • 1. Development and validation of a sensitive solid-phase-extraction and high-performance liquid chromatography assay for the bioreductive agent tirapazamine and its major metabolites in mouse and human plasma for pharmacokinetically guided dose escalation.
    Robin H; Senan S; Workman P; Graham MA
    Cancer Chemother Pharmacol; 1995; 36(3):266-70. PubMed ID: 7781150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trial.
    Graham MA; Senan S; Robin H; Eckhardt N; Lendrem D; Hincks J; Greenslade D; Rampling R; Kaye SB; von Roemeling R; Workman P
    Cancer Chemother Pharmacol; 1997; 40(1):1-10. PubMed ID: 9137522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and bioreductive metabolism of the novel benzotriazine di-N-oxide hypoxic cell cytotoxin tirapazamine (WIN 59075; SR 4233; NSC 130181) in mice.
    Walton MI; Workman P
    J Pharmacol Exp Ther; 1993 May; 265(2):938-47. PubMed ID: 8496834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A column-switching high-performance liquid chromatographic assay for a novel cytotoxic thioxanthone derivative (WIN 33377) in mouse plasma with toxicokinetic results from a mouse LD10 study.
    Drozd ML; Lockwood G; Miller B; Rosi D
    J Chromatogr B Biomed Appl; 1995 Aug; 670(1):145-51. PubMed ID: 7493072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microdialysis sampling with on-line microbore HPLC for the determination of tirapazamine and its reduced metabolites in rats.
    McLaughlin KJ; Faibushevich AA; Lunte CE
    Analyst; 2000 Jan; 125(1):105-10. PubMed ID: 10885067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3-amino-1,2,4-benzotriazine 4-oxide: characterization of a new metabolite arising from bioreductive processing of the antitumor agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine).
    Fuchs T; Chowdhury G; Barnes CL; Gates KS
    J Org Chem; 2001 Jan; 66(1):107-14. PubMed ID: 11429885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I and pharmacokinetic study of tirapazamine (SR 4233) administered every three weeks.
    Senan S; Rampling R; Graham MA; Wilson P; Robin H; Eckardt N; Lawson N; McDonald A; von Roemeling R; Workman P; Kaye SB
    Clin Cancer Res; 1997 Jan; 3(1):31-8. PubMed ID: 9815534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measurement of delivery and metabolism of tirapazamine to tumour tissue using the multilayered cell culture model.
    Kyle AH; Minchinton AI
    Cancer Chemother Pharmacol; 1999; 43(3):213-20. PubMed ID: 9923551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-performance liquid chromatography analysis of a novel small-molecule, anti-cancer drug, Palomid 529, in human and mouse plasma and in mouse tissue homogenates.
    Lin F; Sherris D; Beijnen JH; Van Tellingen O
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Dec; 879(32):3823-31. PubMed ID: 22100549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-performance liquid chromatographic assay for the benzotriazine di-N-oxide (SR 4233) and its reduced metabolites in biological materials.
    Walton MI; Workman P
    J Chromatogr; 1988 Sep; 430(2):429-37. PubMed ID: 3235518
    [No Abstract]   [Full Text] [Related]  

  • 11. Reduction of 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (tirapazamine, WIN 59075, SR 4233) to a DNA-damaging species: a direct role for NADPH:cytochrome P450 oxidoreductase.
    Fitzsimmons SA; Lewis AD; Riley RJ; Workman P
    Carcinogenesis; 1994 Aug; 15(8):1503-10. PubMed ID: 8055626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of NVP-BEZ235, a dual PI3K and mTOR inhibitor, in human and mouse plasma and in mouse tissue homogenates by reversed-phase high-performance liquid chromatography with fluorescence detection.
    Lin F; Chandrasekaran G; de Gooijer MC; Beijnen JH; van Tellingen O
    J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Jul; 901():9-17. PubMed ID: 22727754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of tirapazamine in combination with cisplatin in a single dose every 3 weeks in patients with solid tumors.
    Johnson CA; Kilpatrick D; von Roemeling R; Langer C; Graham MA; Greenslade D; Kennedy G; Keenan E; O'Dwyer PJ
    J Clin Oncol; 1997 Feb; 15(2):773-80. PubMed ID: 9053504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Method for the analysis of S9788, a drug to reverse resistance to anticancer agents, in animal plasma and human plasma and serum by high-performance liquid chromatography with ultraviolet detection.
    Bakes DM; Turner ND; Gordon BH; Hiley MP; Walther B; Lucas C
    J Chromatogr; 1993 May; 615(1):117-26. PubMed ID: 8340450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validated HPLC method for simultaneous quantification of mutant IDH1/2 inhibitors (enasidenib, ivosidenib and vorasidenib) in mouse plasma: Application to a pharmacokinetic study.
    Zakkula A; Dittakavi S; Maniyar MM; Syed N; Sulochana SP; Zainuddin M; Mullangi R
    Biomed Chromatogr; 2019 Nov; 33(11):e4658. PubMed ID: 31325170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tirapazamine-induced DNA damage measured using the comet assay correlates with cytotoxicity towards hypoxic tumour cells in vitro.
    Siim BG; van Zijl PL; Brown JM
    Br J Cancer; 1996 Apr; 73(8):952-60. PubMed ID: 8611431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A validated LC-MS/MS assay for the simultaneous determination of the anti-leukemic agent dasatinib and two pharmacologically active metabolites in human plasma: application to a clinical pharmacokinetic study.
    Furlong MT; Agrawal S; Hawthorne D; Lago M; Unger S; Krueger L; Stouffer B
    J Pharm Biomed Anal; 2012 Jan; 58():130-5. PubMed ID: 21982905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours.
    Brown JM
    Br J Cancer; 1993 Jun; 67(6):1163-70. PubMed ID: 8512801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-performance liquid chromatographic-ultraviolet assay for the simultaneous quantitation of BMS-181101 and its putative hydroxy metabolites in rat and monkey plasma.
    Shah VR; Srinivas NR; Campbell DA; Mantha S; Duncan G; Schuster A; Whigan DW; Shyu WC
    Biomed Chromatogr; 1996; 10(3):135-8. PubMed ID: 8792865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and validation of a sensitive solid-phase extraction and high-performance liquid chromatographic assay for the novel bio-reductive anti-tumor agent RH1 in human and mouse plasma.
    Khan P; Abbas S; Hargreaves RH; Caffrey R; Megram V; McGown A
    J Chromatogr B Biomed Sci Appl; 1999 Jun; 729(1-2):287-95. PubMed ID: 10410954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.